naltrexone has been researched along with Parkinsonian Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambriz-Tututi, M; Drucker-Colín, R; Gómez-Paz, A; Milán-Aldaco, D; Palomero-Rivero, M | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Salvadori, S | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B | 1 |
6 other study(ies) available for naltrexone and Parkinsonian Disorders
| Article | Year |
|---|---|
Intrastriatal Chromospheres' Transplant Reduces Nociception in Hemiparkinsonian Rats.
Topics: Animals; Cells, Cultured; Male; Microinjections; Naltrexone; Nociception; Oxidopamine; Pain Measurement; Parkinsonian Disorders; Rats; Substantia Nigra; Sulpiride | 2018 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
Topics: Amino Acids; Animals; Antiparkinson Agents; Benzimidazoles; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Neural Pathways; Oligopeptides; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thalamus | 2009 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors | 2005 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu | 2001 |